The results demonstrated by Zhu et al. (2020) indicated that Omipalisib suppressed the activation of both PI3K/AKT/mTOR and ERK signaling in all ESCC cell lines, indicating that this inhibitor can suppress MAPK feedback activation. Here, MTOR is linked to esophageal squamous cell carcinoma.